Stryker (NYSE:SYK) updated its FY17 earnings guidance on Tuesday. The company provided earnings per share guidance of $6.45-6.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.48. The company issued revenue guidance of $12.4 billion, compared to the consensus revenue estimate of $12.37 billion.

A number of research analysts have issued reports on the stock. Piper Jaffray Companies increased their target price on shares of Stryker to $166.00 and gave the company an overweight rating in a report on Tuesday. Royal Bank of Canada reaffirmed a buy rating and issued a $175.00 target price on shares of Stryker in a report on Tuesday. Cowen set a $166.00 target price on shares of Stryker and gave the company a buy rating in a report on Sunday, October 29th. Cantor Fitzgerald reaffirmed a neutral rating and issued a $163.00 target price on shares of Stryker in a report on Friday, January 5th. Finally, Needham & Company LLC reaffirmed a hold rating on shares of Stryker in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $156.60.

Stryker (NYSE:SYK) opened at $160.78 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.61 and a current ratio of 2.37. Stryker has a 12 month low of $119.05 and a 12 month high of $164.20. The firm has a market cap of $60,170.00, a P/E ratio of 34.28, a PEG ratio of 2.30 and a beta of 0.78.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analysts’ expectations of $2.97 billion. Stryker had a net margin of 14.67% and a return on equity of 24.11%. Stryker’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same period in the previous year, the company earned $1.39 EPS. research analysts predict that Stryker will post 6.47 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Friday, December 29th will be paid a $0.47 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a yield of 1.17%. The ex-dividend date is Thursday, December 28th. Stryker’s payout ratio is presently 40.09%.

In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of Stryker stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $155.34, for a total value of $776,700.00. Following the completion of the sale, the insider now directly owns 83,207 shares of the company’s stock, valued at approximately $12,925,375.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is currently owned by insiders.

WARNING: “Stryker (SYK) Updates FY17 Earnings Guidance” was posted by Watch List News and is the property of of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Earnings History and Estimates for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with's FREE daily email newsletter.